199 related articles for article (PubMed ID: 33713004)
1. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
Liu WS; Chan SH; Chang HT; Li GC; Tu YT; Tseng HH; Fu TY; Chang HY; Liou HH; Ger LP; Tsai KW
Breast Cancer Res; 2018 Apr; 20(1):25. PubMed ID: 29661250
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
4. The relative isoform expression levels of isocitrate dehydrogenase in breast cancer: IDH2 is a potential target in MDA-MB-231 cells.
Piao S; Kim S; Seo Y; Lee J; Jeon S; Vu GH; Yeo MK; Kim CS
Korean J Clin Oncol; 2023 Dec; 19(2):60-68. PubMed ID: 38229490
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
[TBL] [Abstract][Full Text] [Related]
6. D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation.
Hayashi C; Takagi K; Sato A; Yamaguchi M; Minemura H; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Histol Histopathol; 2021 Oct; 36(10):1053-1062. PubMed ID: 34296423
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Sato A; Takagi K; Miki Y; Yoshimura A; Hara M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2019 Dec; 34(12):1365-1375. PubMed ID: 31149728
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
10. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Das BR; Tangri R; Ahmad F; Roy A; Patole K
Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
[TBL] [Abstract][Full Text] [Related]
11. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
[TBL] [Abstract][Full Text] [Related]
12. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Aljohani AI; Toss MS; Kurozumi S; Joseph C; Aleskandarany MA; Miligy IM; Ansari RE; Mongan NP; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(1):79-90. PubMed ID: 31599393
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
Metellus P; Colin C; Taieb D; Guedj E; Nanni-Metellus I; de Paula AM; Colavolpe C; Fuentes S; Dufour H; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
J Neurooncol; 2011 Dec; 105(3):591-600. PubMed ID: 21643985
[TBL] [Abstract][Full Text] [Related]
18. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Takagi K; Miki Y; Nakamura Y; Hirakawa H; Kakugawa Y; Amano G; Watanabe M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2015 Oct; 30(10):1223-32. PubMed ID: 25873048
[TBL] [Abstract][Full Text] [Related]
19. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management.
Riobello C; López-Hernández A; Cabal VN; García-Marín R; Suárez-Fernández L; Sánchez-Fernández P; Vivanco B; Blanco V; López F; Franchi A; Llorente JL; Hermsen MA
Am J Surg Pathol; 2020 Mar; 44(3):396-405. PubMed ID: 31876581
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor.
Minemura H; Takagi K; Miki Y; Shibahara Y; Nakagawa S; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2015 Nov; 106(11):1642-50. PubMed ID: 26331797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
